63 results about "Retionic Acid" patented technology

The invention discloses retinol retinoate-ceramide lipidosome modified by hyaluronic acid and salts thereof and a preparation method of the retinol retinoate-ceramide lipidosome, and belongs to the technical field of cosmetic nano-carriers. The preparation method comprises the steps that retinol retinoate-ceramide lipidosome is prepared, hyaluronic acid is pretreated, and the hyaluronic acid and the salts thereof are combined to prepare the retinol retinoate-ceramide lipidosome. The liposome is modified by hyaluronic acid and salts thereof in a dual-mechanism manner, and purification and stabilization are realized; the preparation method of the retinol retinoate-ceramide liposome comprises the following steps: dissolving phospholipid, a functionalized lipid component with positive ions and amino functional groups, cholesterol, retinol retinoate and ceramide in absolute ethyl alcohol to serve as an organic phase, taking a phosphate buffer solution as a water phase, dropwise adding the organic phase into the water phase under a stirring condition, stirring, performing ultrasonic treatment, washing, and drying to obtain the retinol retinoate-ceramide liposome. Performing membrane extrusion to obtain a liposome suspension; the retinol retinoate-ceramide liposome modified by hyaluronic acid and salts thereof prepared by the invention has excellent stability, skin transmittance and anti-aging and moisturizing effects, also has low irritation, and is suitable for anti-aging cosmetics.

The invention discloses a method for generating haploid sperm-like cells through in-vitro differentiation of pluripotent stem cells and application of the haploid sperm-like cells. Human pluripotent stem cells are firstly differentiated into ectoderm-like cells, then the ectoderm-like cells are spontaneously gathered and converted into primordial germ cell-like cells under the induction of ectoderm induction factors, and then the primordial germ cell-like cells and testicular sertoli cells are subjected to mixed culture to form recombinant testicular tissues; the recombinant testis tissue enters meiosis under the induction of nutrition limitation and retinoic acid, then meiosis is completed under the stimulation of meiosis second-stage induction factors such as testosterone, follicle-stimulating hormone and pituitary extract, and interaction between primordial germ cell-like cells and testis supporting cells is enhanced by using small molecules SB431542, so that the meiosis of the testis is enhanced. And finally inducing to generate haploid sperm-like cells. According to the invention, a new tool can be provided for researching a molecular mechanism of male reproduction, and an important thought can be provided for research and transformation of asthenospermia, oligospermia, drug screening and the like.

The invention provides efficient mild whitening cream and a preparation method thereof. The raw materials of the cream comprise five phases A and E, the phase C contains 0.1-3% of a mixed solution of isosorbide dimethyl ether and hydroxyl pinacolone retinoate, and the phase D contains 0.01-0.1% of L-carnitine. Wherein the hydroxyl pinacolone retinoate can be specifically combined with an RAR / RXR (Region Receptor / Receptor X Receptor), and the expression of an MITF (Microphthalmia-associated Transcription Factor) gene is reduced, so that the melanogenesis is inhibited; l-carnitine promotes fatty acid beta-oxidation and enhances ATP synthesis to indirectly regulate and control AMPK activity; aMPK enhances transcriptional activity of a tretinoin receptor through phosphorylation of the tretinoin receptor, so that the AMPK and hydroxyl pinacolone retinoate exert a synergistic effect, jointly enhance whitening activity, effectively improve the phenomena of color spots and dark skin and promote the skin color to be uniform, bright and white; meanwhile, the isosorbide dimethyl ether can promote the transdermal absorption of the hydroxyl pinacolone retinoate, the L-carnitine and the related active ingredients.

The main purpose set by the present inventors is to provide a technology for suppressing inflammation particularly in aged tissue in the oral cavity.　The present inventors have discovered that it is possible to suppress inflammation particularly in aged tissue in the oral cavity by an oral cavity composition that contains β-glycyrrhetinic acid and at least one selected from the group consisting of retinol acetate, retinol, all-trans-retinoic acid, ascorbic acid, cobalamin, calciferol, anthraquinone, L-histidine, methylhesperidin, and chemically possible salts thereof.

The present disclosure provides the use of ATDR and ATDRA in the treatment of white matter diseases, and in particular provides all trans-13, 14-dihydroretinol (ATDR) and / or all trans-13, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt comprising all trans-13, 14-dihydroretinol (ATDR) and / or all trans-13, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt comprising all trans-13, 14-dihydroretinoic acid (ATDRA) and / or all trans-13, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof. The present invention relates to a composition comprising 1, 14-dihydroretinoic acid (ATDRA) or a pharmaceutically acceptable salt thereof, retinol saturase (Retsat) or a variant thereof, a nucleic acid encoding Retsat or a variant thereof, an expression cassette comprising a nucleic acid encoding Retsat or a variant thereof, a vector comprising a nucleic acid encoding Retsat or a variant thereof, and a method for preparing the same. Use of a cell expressing Retsat or a variant thereof for the preparation of a medicament for the prevention and / or treatment of leukoencephalopathy in a subject in need thereof, which promotes oligodendrocyte differentiation and myelination to thereby treat leukoencephalopathy.

The invention discloses a whitening and brightening composition and a cosmetic thereof. The whitening and brightening composition is prepared from ascorbyl tetraisopalmitate, tranexamic acid, Brigtenyl, LightSKN CN, a resveratrol fermentation product, fermented lotus essence and super vitamin A, brigtenyl is a mixture composed of a first solvent, glycerin and diglucosyl gallic acid; lightSKN CN is a mixture composed of a second solvent, 1, 3-propylene glycol, xanthophyll, lecithin, sodium ascorbate and vitamin E; the resveratrol fermentation product is a mixture composed of a third solvent, a pichia pastoris fermentation lysate filtrate and resveratrol; the fermented lotus seed essence is a mixture composed of a fourth solvent, butanediol and a lotus seed extract; the super vitamin A is a mixture of isosorbide dimethyl ether and hydroxyl pinacolone retinoate. The whitening and brightening composition not only can inhibit melanin generation, reduce melanin transfer and accelerate melanin metabolism, but also can remove excessive free radicals in skin, so that the effects of long-acting skin whitening and skin brightening are achieved.

The present invention relates to a method for producing neuronal cells from dedifferentiated adipocytes derived from a mammal, the method comprising a step for culturing dedifferentiated adipocytes derived from a mammal using a medium that contains a basic fibroblast growth factor (bFGF), retinoic acid, and a neuronal differentiation inducer, but does not substantially contain an epigenetic inhibitor.

This invention discloses a multi-target anti-aging composition and its application in cosmetics. By weight, it comprises the following ingredients: 0.001–3 parts hydroxypinazone retinate, 0.01–5 parts hydroxypropyl tetrahydropyranotriol, 0.01–0.5 parts recombinant human collagen, 0.5–3 parts tocopheryl acetate, 0.1–5 parts glyceryl glucoside, 0.01–5 parts Babao Essence Extract, 0.01–0.5 parts carnosine, 0.5–2 parts 3000 peptides, 0.1–5 parts Bifida ferment lysate, 0.01–0.5 parts coenzyme Q10, and 0.1–5 parts black tea fermentation product. This multi-target anti-aging composition targets four aspects: anti-aging, anti-oxidation, anti-glycation, and anti-photochemical activity. The four categories of components work synergistically to significantly enhance the anti-aging efficacy of the product. Human efficacy evaluation tests show that after using the product of this invention for 28 days, the elasticity of the skin around the eyes is significantly increased, the firmness and roughness of the skin around the eyes are significantly improved, and the area, volume and depth of wrinkles at the corners of the eyes are significantly improved.

The invention discloses a method for synthesizing retinoic acid ceramide ester through enzyme catalysis and application of the retinoic acid ceramide ester, and belongs to the technical field of cosmetic raw material synthesis. According to the method, retinoic acid and ceramide NP serve as substrates, specific immobilized lipase serves as a catalyst, and in a non-aqueous phase organic solvent, the target product is efficiently synthesized through the steps of raw material preparation, anaerobic reaction system building, directional esterification reaction, aftertreatment and purification detection. The method solves the problems of low substrate solubility, more byproducts, difficulty in catalyst recovery and the like in the traditional process, has the advantages of mild reaction conditions, capability of retaining the activity of the raw materials, high product purity and anti-aging and barrier repair effects, and can be widely used for preparing raw materials of anti-wrinkle and repair cosmetics.

The present invention relates to a process for producing a population of cells which comprises mature atrial cardiomyocytes. The process comprises the step of treating iPS cells according to a treatment regimen which comprises contacting the iPS cells with Gremlin2 and retinoic acid, such that at least a portion of the iPS cells differentiate into mature atrial cardiomyocytes.

The present disclosure relates to a method for predicting the response of a metastasis to immunotherapy in a metastatic colorectal cancer patient. The present disclosure also encompasses an immunotherapy for use in the treatment of a metastatic colorectal cancer in a patient in need thereof previously identified as having a metastasis responsive to immunotherapy and an immune-stimulating agent for use in the treatment of a metastatic colorectal cancer in a patient in need thereof previously identified as having a metastasis non-responsive to immunotherapy. The present disclosure also relates to a pharmaceutical composition comprising an immune-stimulating agent and retinoic acid for use in the treatment of a metastatic colorectal cancer in a patient in need thereof.

A water-in-oil emulsion with an aqueous and an oil phase, such that the oil phase comprises at least one oil-soluble sunscreen, a functional elastomer, a retinoic acid precursor and a substituted resorcinol.

An oil-in-water emulsion having an SPF of at least 25, comprising: (a) at least 0.01 wt.% of one or more types of retinol selected from the group consisting of retinol, retinaldehyde, retinoic acid, or a combination thereof; (b) one or more water soluble antioxidants; (c) one or more oil soluble antioxidants; (d) at least 10 wt.% of one or more oil soluble or oil dispersible sunscreen components. Methods of making the oil-in-water emulsions as well as uses and methods of use of the oil-in-water emulsions.

The invention belongs to the technical field of cell biology, and particularly relates to a culture medium for amplifying Treg cells, a culture method and application. The culture medium comprises an activation culture medium and an amplification culture medium, wherein the activated culture medium is prepared from a serum-free culture medium, IL-2 (Interleukin-2), TGF (Transforming Growth Factor)-beta (beta), rapamycin, IL-27 (Interleukin-27), retinoic acid and Anti-Human CD3 / CD28 beads; the amplification culture medium comprises a serum-free culture medium, IL-2, rapamycin and IL-27. According to the invention, the culture medium combination with a specific formula and proportion is adopted, and the synergistic effect of the IL-2, the TGF-beta, the rapamycin, the IL-27, the retinoic acid and the Anti-Human CD3 / CD28 beads is utilized, so that the amplification multiple and the immunosuppression capability of the Treg cells are remarkably improved. The invention provides a more efficient and safer technical scheme for clinical application of Treg cell therapy.

The present invention relates to use of a personal care composition comprising a heteroaromatic compound selected from nicotinic acid, picolinic acid, niacin, niacinamide, picolinamide and mixtures thereof, a retinoic acid precursor selected from retinyl esters, retinol, retinal, retinoic acid and mixtures thereof, a resorcinol compound; and an oil-soluble sunscreen, for improving the barrier function of skin.

This invention discloses a composition for the differentiation of mesenchymal stem cells (ADSCs) into keratinocytes and its application. The composition comprises: a Wnt signaling pathway activator, a TGF-β signaling pathway inhibitor, a bone morphogenetic protein pathway activator, and at least one of retinoic acid and a retinoic acid agonist. The small molecule composition provided by this invention is meticulously designed to gradually guide the fate transition of ADSCs by mimicking key signaling events during embryonic development. This strategy is not a simple compound screening, but a rational design based on a deep understanding of developmental biology, achieving precise regulation of cell lineages in vitro by reproducing the natural developmental process. The composition of this invention is not a simple superposition of components, but rather achieves cell fate transition by precisely regulating the balance of signaling pathway networks.

The method for producing a cell aggregate including glial progenitor cells according to the present invention comprises:(1) a step of subjecting pluripotent stem cells to suspension culture in an embryoid-body-forming culture medium containing one or more SMAD signaling inhibitors and one or more Wnt signaling activators in the absence of feeder cells for 5 days to 10 days, to form a cell aggregate;(2) a step of subjecting the cell aggregate obtained in (1) to suspension culture in an embryoid-body-forming culture medium containing retinoic acid;(3) a step of subjecting the cell aggregate obtained in (2) to suspension culture in an embryoid-body-forming culture medium or neuron-and-glia-proliferating culture medium containing retinoic acid and one or more SHH signaling activators; and(4) a step of subjecting the cell aggregate obtained in (3) to suspension culture in a neuron-and-glia-proliferating culture medium containing no retinoic acid and one or more SHH signaling activators.

The invention belongs to the technical field of biological medicines, and particularly relates to a tumor neoantigen peptide induced by retinoic acid and application of the tumor neoantigen peptide. According to the invention, an endogenous retrovirus expression profile is used as a new antigen source and a biomarker independent of TMB for the first time. Even for'cold tumors' (such as prostatic cancer and glioma) with extremely low TMB (Tetramethylbenzidine), as long as abnormal activation of ERV (such as using all-trans retinoic acid in the invention) exists, abundant targets with immunogenicity can be identified, applicable people and cancer types of new antigen immunotherapy are greatly expanded, and the application prospect is wide. The fundamental bottleneck that the prior art is limited by TMB is solved. Based on the method, the novel tumor antigen peptide TWQRYNK is identified, and the tumor growth can be limited and the sensitivity to ICB treatment can be improved when the antigen peptide is independently used or combined with ICB.

The invention discloses bifidobacterium breve for regulating metabolism of vitamin A in intestinal flora and application of the bifidobacterium breve, and belongs to the field of microorganisms. According to the bifidobacterium breve CCFM1489 disclosed by the invention, vitamin A can be subjected to external metabolism to generate retinoic acid; corneal injury and conjunctival goblet cell injury of mice with xerophthalmia are relieved; the RA level in serum of the dry-eye mouse is improved; the levels of IL-6, IL-17 and TNF-alpha in serum of the mouse with the dry eye syndrome are reduced, the intestinal flora of the mouse with the dry eye syndrome is regulated, and the abundance of beneficial bacteria is increased. Therefore, the bifidobacterium breve CCFM1489 has a huge application prospect in preparation of products for preventing and / or relieving xerophthalmia.

A pharmaceutical composition containing a stem cell secretion, and a pharmaceutically acceptable excipient thereof. The protein in the stem cell secretion comprises one, two or three proteins selected from a group consisting of a pigment epithelium-derived factor (PEDF), a tissue inhibitor of metalloproteinase 1 (TIMP-1), a secreted protein acidic and rich in cysteine (SPARC), an α2-HS glycoprotein (AHSG), a periostin (POSTN), a decorin (DCN), the retinoic acid receptor responder 2 (RARRES2), the glia-derived nexin (GDN), the Sparc / osteonectin, cwcv and kazal like domains proteoglycan 1 (SPOCK1), and the follistatin-like 1 (FSTL1). The pharmaceutical composition is used for treating degenerative ocular diseases including retinal degeneration, retinitis pigmentosa, glaucoma, macular degeneration, etc.

The application discloses an anti-aging composition and application thereof. The anti-aging composition is prepared by compounding dimethylsilyl hyaluronate, radix pseudoginseng cyclic peptide B and alfalfa extract. The alfalfa extract is obtained by adopting pulse ultrasonic assisted subcritical extraction technology, and can play a better anti-aging effect. The experiment proves that the composition can significantly improve the contents of retinoic acid binding receptor RAR alpha and RXR gamma protein and type I collagen protein, inhibit cell aging, and achieve an anti-aging effect similar to retinol. Compared with retinol, the composition is mild and non-irritating, can significantly improve the preservative efficiency of a product in skin care, and can reduce the amount of preservatives.

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

This present disclosure provides various diamine centered poly(amino acid)-saccharide-lipid conjugates. In various embodiments, the conjugates can safely be used as water solubility or bioavailability enhancers. In one aspect, the present disclosure provides a conjugate having the structural formula wherein B is a residue of a compound having three or four available binding positions, e.g., an alkylene diamine; S is a saccharide, for example, a residue of a mono-, di- or trisaccharide group, in which each saccharide unit is a sugar, a sugar alcohol, an amino sugar or a sugar acid; L is a lipophilic carrier residue selected from fatty acid residues (for example, residues of lauric acid, myristic acid, linoleic acid, palmitic acid, oleic acid and elaidic acid), steroid acid and sterol residues, and residues of retinoids carotenoids, tocopherols, and tocotrienols; Q is a residue of ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol or hexaethylene glycol; P is a residue of a polyaminoacid homopolymer; R2 is a terminal group selected from H, methyl, ethyl and maleimide; D is a secondary group that is as defined above for L or is a methyl-capped poly(ethylene glycol) residue; and d is 0, or d is 1.

The invention discloses a stomach body three-dimensional organoid culture medium as well as a preparation method and a culture method thereof, and belongs to the technical field of organoid culture. The stomach body three-dimensional organoid culture medium comprises a basic culture medium and a stomach body organoid growth supplement, the stomach body organoid growth supplement comprises a Wnt signaling pathway agonist, an FGF (Fibroblast Growth Factor) family member, a TGF-beta signaling pathway inhibitor, hyaluronic acid and retinoic acid. The invention further discloses a preparation method of the gastric body three-dimensional organoid culture medium and a gastric body three-dimensional organoid culture method. The method can solve the problems that the existing organoid culture technology is difficult to effectively maintain and amplify the stomach organoid with the functional oxyntocytes, and the existing organoid culture technology has unstable pedigree and incomplete structure.

The invention discloses a high-stability retinol composite nano-liposome and a preparation method thereof, and the high-stability retinol composite nano-liposome comprises glycerol, water, 2, 3-butanediol, caprylic / capric triglyceride, 1, 2-hexanediol, retinol, hydroxyl pinacolone retinate and a synergistic modified lipid, wherein the synergistic modified lipid is composed of sodium stearoyl glutamate, polysorbate-20 and polyglycerol-4 oleate, and the retinol and the hydroxyl pinacolone retinoate serve as retinoid active substances and are jointly wrapped in a nanoscale liposome structure formed by self-assembly of the synergistic modified lipid. The preparation method comprises the steps of water phase preparation, oil phase preparation, mutual mixing, synergistic modified lipid addition and dispersion treatment. According to the invention, stable wrapping of double retinoid active matters is realized through synergistic modification of a lipid system, the stability and the utilization rate of the retinoid active matters can be effectively improved, and the irritation is reduced while the efficacy is ensured.

The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.

This application relates to a microbial oil composition containing retinoids and fatty acids, a cosmetic composition, a food composition, a feed composition containing the same, and a method for producing the same.

By means of co-expression interference on expression of retinoic acid-induced gene I (RIG-1), virus transfection in transfection cells and expression of recombinant virus payload are enhanced. In some embodiments, the co-expression is driven by a tissue-specific promoter.

The invention discloses a retinoic acid derivative as well as a preparation method and application thereof, and belongs to the technical field of cosmetic raw materials. The derivative is raspberry ketone retinoate, and the structural formula of the derivative is shown in the specification.

The invention provides a transcription factor (ROR beta) of a biomarker retinoic acid-related orphan receptor beta (retinoic acid-related orphan receptor beta) and an application of the transcription factor in BD-related diseases, and the application comprises application of the biomarker in preparation of a bipolar affective disorder (bipolar affective disorder, BD-related diseases). The invention relates to a biomarker, a diagnostic product for BD-related diseases, a drug for treating and / or preventing BD-related diseases, and application of the biomarker in screening of drugs for treating and / or preventing BD-related diseases. The biomarker is a detection target of the diagnostic product and a treatment, prevention and / or screening target of the drug. According to the invention, the correlation between ROR beta and BD disease occurrence through a pancreas-hippocampus feedback loop mechanism is determined for the first time, and a plasma sample can be detected, so that the convenience of detecting and screening medicines is improved.